An interventional study of Protein restriction in CKD Stage 4, sponsored by Anemia Working Group Romania. Status unknown at 1 site in Romania. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2020-02-24.
Sponsored by Anemia Working Group Romania · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a prospective single center open label randomized controlled trial aiming to assess the effectiveness and safety of a low protein diet (0.6 g/kg-day, mainly vegetarian) supplemented with ketoanalogues of essential amino-acids (sLPD) as compared to a mild protein restriction (0.8 g/kg-day, MPD) in reducing Chronic Kidney Disease (CKD) progression, with a planned total duration is of 18 months.
Adult diabetic patients with CKD stage 4+ [estimated glomerular filtration rate (eGFR) using the Modification of Diet in Renal Disease 4-variable (MDRD4) formula \<30 mL/min per year], with stable renal function (historical reduction of eGFR of \< 10 ml/min-year) , proteinuria > 3g/g creatininuria and good nutritional status (SGA A) will be enrolled.
Adult diabetic patients with Chronic Kidney Disease (CKD) stage 4+ (estimated GFR using the Modification of Diet in Renal Disease 4-variable, MDRD4, formula \<30 mL/min per year), with stable renal function (historical reduction of eGFR of \< 10 ml/min-year), proteinuria > 3g/g creatininuria and good nutritional status (SGA A) will be enrolled. Patients with evidence of active kidney disease (except proteinuria), with indication of etiological or pathogenic treatment, those with poor control of diabetes (HbA1c >8%), those with uncontrolled high blood pressure (≥155/85 mmHg), those with significant co-morbidities (heart failure, active liver disease, malabsorption, active infections, inflammatory diseases requiring corticosteroids), those with uremic symptoms (pericarditis, digestive disorders ) or malnutrition (SGA B or C, serum albumin \< 3.5 g/dl) will be excluded.
Eligible patients will enter a run-in phase (3 mo), when mild protein restriction (0.8g/kg dry ideal bw) will be initiated and compliance will be evaluated twice monthly.
Those who will prove compliant during the run-in phase and still fulfill the selection criteria will be randomized 1:1 (computer-generated numbers) to receive the low protein diet (0.6 g/kg-day, mainly vegetarian) supplemented with ketoanalogues of essential amino-acids (Ketosteril 1 tb/10 kg dry bw) or to continue the mild protein restriction (0.8 g/kg-day).
The total recommended energy intake is of 30 kcal/kg of ideal dry body weight per day in all patients.
The primary composite endpoint is the need for RRT initiation or a more than 50% reduction in the initial eGFR any time during the assessment phase. The decision to initiate RRT will be made by the Ethical Committee of the Hospital, based on the clinical and laboratory data.
The need for RRT initiation, the quality of life [assessed by the Short Form-36 (SF-36) Questionnaire], the decline in GFR and the correction of metabolic complications of CKD [serum levels of urea, calcium, phosphates, serum parathyroid hormone levels, bicarbonate, potassium] will be secondary efficacy parameters.
Parameters of nutritional status (SGA, anthropometric and biochemical parameters), compliance to the diet, occurrence of any adverse event and the number of withdrawals will be safety variables.
All the parameters will be assessed at baseline, throughout the intervention phase and at end of the study.
544 studies on the registry are indexed under Diabetic Nephropathies; 110 are open to participants now.
This study's planned enrollment of 120 is above the median of 78 across 389 interventional studies indexed under Diabetic Nephropathies.
Browse Diabetic Nephropathies studies →Anemia Working Group Romania is the lead sponsor of 9 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Protein restriction to a low level (0.6 g/kg-day, mainly vegetarian) + ketoanalogues of essential amino-acids supplementation (Ketosteril 1 tb/10 kg dry bw)
Behavioral: Protein restriction
Mild restriction in dietary protein intake (0.8 g/kg-day)
Behavioral: Protein restriction
In both arms the dietary protein intake will be reduced. In the sLPD arm, the protein restriction is more severe and ketoanalogues of the essential aminoacids are offered.
CKD progression
Percentage of patients requiring RRT initiation or a more than 50% reduction in the initial eGFR at anytime during the study
Time frame: 15 months
Need for renal replacement therapy (RRT)
Percentage of patients requiring RRT during the study
Time frame: 15 months
Patients' Quality of life
Patients' Quality of life, assessed by the SF-36 Questionnaire
Time frame: at baseline and than every 3 months up to 15 months
Decline in eGFR
Difference between eGFR at any timepoint and the initial eGFR
Time frame: monthly up to 15 months
Correction of nitrogen balance
Serum urea
Time frame: monthly up to 15 months
Correction of metabolic acidosis
Serum bicarbonate
Time frame: monthly up to 15 months
Correction of calcium metabolism abnormalities
Serum calcium
Time frame: monthly up to 15 months
Correction of mineral metabolism abnormalities
Serum phosphates
Time frame: monthly up to 15 months
Serum level of intact Parathyroid Hormone (iPTH)
iPTH
Time frame: monthly up to 15 months
Nutritional status - Subjective Global Assessment (SGA)
SGA
Time frame: monthly up to 15 months
Body Mass Index (BMI)
BMI
Time frame: monthly up to 15 months
Tricipital Skin Fold (TSF)
TSF
Time frame: monthly up to 15 months
Middle arm muscular circumference (MAMC)
MAMC
Time frame: monthly up to 15 months
Serum albumin
Serum albumin
Time frame: monthly up to 15 months
Serum cholesterol
Serum cholesterol
Time frame: monthly up to 15 months
Inflammatory status
Serum C-Reactive Protein (CRP)
Time frame: monthly up to 15 months
Compliance to the protein intake
Achieved protein intake (urinary urea excretion, Mitch-Maroni's formula)
Time frame: twice-a-month during the run-in phase, weekly for the first month after randomization, every 4 weeks during the next 6 months, and then every 3 months up to 15 months
Compliance to the energy intake
Achieved energy intake (3-days food dairy)
Time frame: twice-a-month during the run-in phase, weekly for the first month after randomization, every 4 weeks during the next 6 months, and then every 3 months up to 15 months
Occurence of the adverse events
Occurence of any adverse event
Time frame: twice-a-month during the run-in phase, weekly for the first month after randomization, every 4 weeks during the next 6 months, and every 3 months up to 15 months
Plan to share: Yes — Unique patient number in the study, biological data; no data to enable patient identification will be provided
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: March 2022
Started Oct 2019 (actual). Primary completion is estimated for Sep 2022, 35 months after the start.
Of 50 non-industry interventional studies with no phase under Diabetic Nephropathies, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 37. This study's planned 35 months is above that.
Counting every sponsor, half of 51 studies reached it within 23 months; a quarter within 11 and three quarters within 37.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Anemia Working Group Romania